Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P43166
UPID:
CAH7_HUMAN
Alternative names:
Carbonate dehydratase VII; Carbonic anhydrase VII
Alternative UPACC:
P43166; Q541F0; Q86YU0
Background:
Carbonic anhydrase 7 (CA7), also known as Carbonate dehydratase VII, plays a crucial role in the reversible hydration of carbon dioxide. This enzyme is part of the carbonic anhydrase family, which is vital for maintaining acid-base balance in various tissues and facilitating CO2 transport.
Therapeutic significance:
Understanding the role of Carbonic anhydrase 7 could open doors to potential therapeutic strategies. Its function in CO2 hydration and acid-base balance positions it as a key target for research in disorders related to these processes.